Ganirelix

Ganirelix is a competitive and selective gonadotropin releasing hormone (GnRH) antagonist. Ganirelix prevents endogenous GnRH from inducing luteinising hormone (LH) and follicle stimulating hormone relea[1].

Product Specifications

CAS Number

[124904-93-4]

UNSPSC

12352209

Hazard Statement

H302, H312, H332

Target

GnRH Receptor

Type

Peptides

Related Pathways

GPCR/G Protein

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/ganirelix.html

Purity

99.88

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

C([C@@H](NC([C@@H](NC([C@H](NC([C@H](CC1=CC=C(O)C=C1)NC([C@@H](NC([C@H](NC([C@@H](CC2=CC=C(Cl)C=C2)NC([C@@H](CC3=CC4=C(C=C3)C=CC=C4)NC(C)=O)=O)=O)CC=5C=CC=NC5)=O)CO)=O)=O)CCCCN=C(NCC)NCC)=O)CC(C)C)=O)CCCCN=C(NCC)NCC)(=O)N6[C@H](C(N[C@@H](C(N)=O)C)=O)CCC6

Molecular Formula

C80H113ClN18O13

Molecular Weight

1570.32

Precautions

H302, H312, H332

References & Citations

[1]Gillies PS, et al. Ganirelix. Drugs. 2000 Jan;59 (1) :107-11; discussion 112-3.|[2]Russo A, et al. Effects of the gonadotropin-releasing hormone antagonist ganirelix on normal micturition and prostaglandin E (2) -induced detrusor overactivity in conscious female rats. Eur Urol. 2011 May;59 (5) :868-74.